Olanzapine is an antipsychotic, thienobenzodiazepine compound that has been approved for use in the treatment of schizophrenia and bipolar disorder (formulated for human use under the name Zyprexa?). Olanzapine binds as an antagonist/inverse agonist to dopamine D1 (Ki = 31 nM), dopamine D2 (Ki = 11 nM), dopamine D4 (Ki = 27 nM), serotonin 5-HT2A (Ki = 4 nM), serotonin 5-HT2C (Ki = 11 nM), serotonin 5-HT3 (Ki = 57 nM), muscarinic M1 (Ki = 2 nM), α1-adrenergic (Ki = 19 nM), and histamine H1 (Ki = 7 nM) receptors. Olanzapine has a high affinity for dopamine D1 and D2 receptors (IC50s = 25 and 10 nM, respectively) in human striatal tissue and for 5-HT2A, 5-HT2C, muscarinic M1, and α1-adrenergic receptors (IC50s = 7, 71, 2, and 70 nM, respectively) in human frontal cortex. This product is intended for research purposes only.
